Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

LAB
The Conversation (0)
Blackrock Silver Extends Silver and Gold to Northwest at Tonopah West

Blackrock Silver Extends Silver and Gold to Northwest at Tonopah West

The NW Stepout Drill Program Extends Mineralization Another 600 Metres to the Northwest Along the Projection of the Denver Vein System, and Identifies Mineralized Intrusive Complex Target Blackrock Silver Corp. (TSXV: BRC,OTC:BKRRF) (OTCQX: BKRRF) (FSE: AHZ0) ("Blackrock" or the "Company")... Keep Reading...
Nevada's Oxide Gold Districts Are Being Redrilled for a Second Metal

Nevada's Oxide Gold Districts Are Being Redrilled for a Second Metal

American News Group News Commentary - Nevada has been drilled for gold for fifty years, and the assay suites used for most of that period were built to find gold. Antimony, when it was present, was frequently not assayed for at all, or was recorded and then ignored because it had no value worth... Keep Reading...
NevGold Intercepts 1.06 g/t Oxide Au Over 42.7 Meters Outside of 2026 MRE Pit-shell; Mineralization Also Expanded Inside Pit-Shell With 5.00 g/t Oxide Au Over 3.0 Meters Within 1.23 g/t Oxide Au Over 27.4 Meters at Limo Butte, Nevada

NevGold Intercepts 1.06 g/t Oxide Au Over 42.7 Meters Outside of 2026 MRE Pit-shell; Mineralization Also Expanded Inside Pit-Shell With 5.00 g/t Oxide Au Over 3.0 Meters Within 1.23 g/t Oxide Au Over 27.4 Meters at Limo Butte, Nevada

Nevgold Corp. ("NevGold" or the "Company") (TSXV:NAU,OTC:NAUFF) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce additional oxide-gold assays from the 2026 drill program at its Limousine Butte Project (the "Project", "Limo Butte") in Nevada. These results have significantly expanded oxide... Keep Reading...
Fathom Announces New Zones of Mineralization Highlighting Exploration Potential of Recently Announced Gochager Lake Ni-Cu-Co Deposit Maiden MRE

Fathom Announces New Zones of Mineralization Highlighting Exploration Potential of Recently Announced Gochager Lake Ni-Cu-Co Deposit Maiden MRE

Fathom Nickel Inc. (CSE: FNI,OTC:FNICF) (FSE: 6Q5) (OTCQB: FNICF) ("Fathom", or the "Company") is pleased to announce the discovery of new zones of nickel-copper-cobalt mineralization highlighting the exploration potential of recently announced maiden Mineral Resource Estimate ("the MRE") at the... Keep Reading...
Peruvian Metals Corp. Commences Underground Development to Access High-Grade Au-Ag Sulphides at Palta Dorada

Peruvian Metals Corp. Commences Underground Development to Access High-Grade Au-Ag Sulphides at Palta Dorada

Peruvian Metals Corp (TSXV: PER,OTC:DUVNF) (OTC Pink: DUVNF) ("Peruvian Metals" or the "Company") is pleased to announce that the Company has commenced underground development at its 100% owned Palta Dorada Gold-Silver property (the "Property") located in the Ancash department in Northern Peru.... Keep Reading...
Lexaria Updates Financial Position

Lexaria Updates Financial Position

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax... Keep Reading...
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the... Keep Reading...
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to... Keep Reading...
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September... Keep Reading...
BriaCell Therapeutics (TSX:BCT)

BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation

Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical... Keep Reading...
Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received... Keep Reading...

Interactive Chart

Latest Press Releases

Related News